Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy

NCT04703244 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04703244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04703244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
January 13, 2021
Completion date
January 15, 2042
Enrollment
999 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, residual